Valuation: Cocrystal Pharma Inc

Market Cap 18.3M 16.68M 15.37M 13.98M 26.24M 1.7B 27.63M 187M 74.3M 926M 68.66M 67.22M 2.9B P/E 2026 *
-1.23x
P/E 2027 * -1.73x
Enterprise Value 18.3M 16.68M 15.37M 13.98M 26.24M 1.7B 27.63M 187M 74.3M 926M 68.66M 67.22M 2.9B EV / Sales 2026 *
73.2x
EV / Sales 2027 * -
Free-Float
77.59%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 2026-06-02
Chief Executive Officer 59 2021-05-26
Chief Executive Officer 66 2021-05-26
Director TitleAgeSince
Director/Board Member 89 2014-01-01
Chairman 79 2021-05-26
Director/Board Member 65 2014-01-01
Change 5-day change 1-year change 3-year change Capi.($)
-6.38%-6.38% - - 18.3M
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.87B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -1.87%-1.22%+33.07%+180.54% 44B
Weighted average by Cap. -1.48%-1.85%+31.83%+155.14%

Financials

2026 *2027 *
Net sales 250K 228K 210K 191K 358K 23.16M 377K 2.55M 1.01M 12.65M 938K 918K 39.63M -
Net income -11.7M -10.67M -9.82M -8.94M -16.78M -1.08B -17.66M -119M -47.5M -592M -43.89M -42.97M -1.85B -10.75M -9.8M -9.03M -8.21M -15.41M -996M -16.23M -110M -43.64M -544M -40.33M -39.48M -1.7B
Net Debt - -
Logo Cocrystal Pharma Inc
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cocrystal Pharma Inc
BLACK FRIDAY -Get 40% off all subscriptions
BLACK FRIDAY40% off all subscriptions
Get the offer